DL-α-Difluoromethylornithine Hydrochloride (DFMO) #69294
Product Information
Product Usage Information
Storage
Product Description
| Molecular Weight | 236.7 g/mol |
| Purity | >98% |
| Molecular Formula | C6H12F2N2 O2 • HCl • H2O |
| CAS | 96020-91-6 |
| Solubility | Soluble in water at 25 mg/mL. |
Background
The polyamine analog DL-α-Difluoromethylornithine Hydrochloride (DFMO) inhibits the enzyme ornithine decarboxylase (ODC), which catalyzes the rate-limiting step of polyamine biosynthesis. Originally developed to treat excessive hair growth and trypanosomiasis, DFMO was later studied as a potential therapeutic to block the development of cancers that relied on polyamine biosynthesis (1). Blocking polyamine biosynthesis with DFMO in conjunction with the drug-induced inhibition of polyamine uptake prevented or delayed tumor development in neuroblastoma-prone mice, and extended survival in rodent models of established tumors (2). Treatment with DFMO suppressed oncogene MYC expression and MYC-mediated tumorigenesis, and improved treatment of chemoresistant pancreatic ductal adenocarcinoma (3). Inhibition of ODC by DFMO blocked tumor growth in intact immunocompetent mice, but not in immunodeficient individuals. Specifically, DFMO promoted an immunological response to cancer as treatment of mice increased anti-tumor CD8+ T cell infiltration and IFN-γ production, augmented the efficacy of adoptive T cell therapy, and impaired myeloid-derived suppressor cell activity (4).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.